35results about How to "Avoid neurotoxicity" patented technology

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of Δ6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.

Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

The use of a compound of formula (I), is disclosed in treating and / or preventing 5 chemotherapy-induced peripheral neurotoxicity (CIPN). The invention includes pharmaceutical compositions wherein the compound of formula (I) is present in a mixture with anticancer agents. An improved anticancer treatment with reduced CIPN-related side effects is also provided.

The embodiment of the invention provides a corrosion-resistant high strength and toughness magnesium alloy tubular product and a preparation process. The alloy tubular product is prepared from the following elements in percent by mass: 1.0-6.0% of Nd, 0.1-5.0% of Zn, 0.1-5.0% of Ca, 0.1-4.0% of Zr and the balance Mg. The preparation process comprises the following steps: successively preparing a magnesium alloy cast ingot, a magnesium alloy blank, a magnesium round bar and a magnesium hollow round ingot through a series of steps: vacuum semicontinuous casting, solid solution homogenizing, barextrusion processing, hollow round ingot processing and the like; and finally, extruding the hollow round ingot to obtain the corrosion-resistant high strength and toughness magnesium alloy tubular product. The corrosion-resistant high strength and toughness magnesium alloy tubular product solves the problem of hard plastic processing for preparing a bracket as the magnesium alloy tubular productis relatively poor in deformability at room temperature in the prior art, can be degraded uniformly in vivo while achieving an ideal supporting effect of the alloy, and meanwhile, has better corrosionresistance and is relatively uniform to corrode, wherein the corrosion rate is 0.18-0.42 mm / year.

The embodiment of the invention provides high-strength-and-toughness and corrosion-resistance magnesium alloy and a preparation method thereof. The alloy solves the problems in the prior art that thedeformation capability of the magnesium alloy is poorer and the plasticity processing is difficult when the magnesium alloy is used for preparing stents, the stents can be uniformly degraded in the body while the ideal supporting effect of alloy is achieved, better corrosion resistant performance is achieved, the corrosion-resistance rate is significantly reduced, and the corrosion is more uniform.